

Dedee Murrell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8603576/publications.pdf>

Version: 2024-02-01

229
papers

9,298
citations

41344

49
h-index

45317

90
g-index

299
all docs

299
docs citations

299
times ranked

6885
citing authors

#	ARTICLE	IF	CITATIONS
1	Dermatoethics: Nepotism in dermatology residencies. <i>Journal of the American Academy of Dermatology</i> , 2023, 89, 193-194.	1.2	0
2	Recommendations on pregnancy, childbirth and aftercare in epidermolysis bullosa: a consensus-based guideline*. <i>British Journal of Dermatology</i> , 2022, 186, 620-632.	1.5	4
3	Clinical features of chronic bullous dermatosis of childhood. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 873-881.	1.3	2
4	Biological medication in atopic dermatitis. <i>Expert Opinion on Biological Therapy</i> , 2022, , 1-7.	3.1	5
5	Dupilumab-associated ocular manifestations: A review of clinical presentations and management. <i>Survey of Ophthalmology</i> , 2022, 67, 1419-1442.	4.0	12
6	Sebaceous cell carcinoma presenting as ocular Marjolin ulcer following immunosuppression for a chemical burn. <i>Canadian Journal of Ophthalmology</i> , 2022, , .	0.7	0
7	Psoriasis and osteoporosis: a literature review. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 1438-1445.	1.3	9
8	How Do Experts Treat Patients with Bullous Pemphigoid around the World? An International Survey. <i>JID Innovations</i> , 2022, 2, 100129.	2.4	2
9	Allergic contact dermatitis to miconazole for nipple candidiasis. <i>Contact Dermatitis</i> , 2022, 87, 201-202.	1.4	3
10	Mental health, insomnia and suicidal ideation during treatment with apremilast. <i>Australasian Journal of Dermatology</i> , 2022, 63, 403-404.	0.7	2
11	Assessing quality of life in patients with autoimmune bullous diseases using the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life questionnaire finds similar effects in women as men. <i>International Journal of Women's Dermatology</i> , 2022, 8, e004.	2.0	2
12	Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgaris. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	3
13	Proposed management algorithm for dupilumab-associated ocular side effects: a collaborative effort between dermatologists and ophthalmologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	0
14	A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, .	2.7	2
15	Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1161-1167.	1.2	24
16	Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1107-1109.e2.	2.9	18
17	Ectropion surgery might not be a long-term solution for harlequin ichthyosis. <i>Dermatologic Therapy</i> , 2021, 34, e14646.	1.7	1
18	Authors' reply to the comment "Treatment considerations for patients with pemphigus during the COVID-19 pandemic". <i>Journal of the American Academy of Dermatology</i> , 2021, 84, e61-e62.	1.2	4

#	ARTICLE	IF	CITATIONS
19	An analysis of the prevalence of osteoporosis and osteopenia in patients with epidermolysis bullosa: A cross-sectional study. <i>Experimental Dermatology</i> , 2021, 30, 1675-1685.	2.9	3
20	Cardiac Involvement in Epidermolysis Bullosa. , 2021, , 33-48.		0
21	The Importance of Cardiac Assessment in the Era of Biologic Therapies for Psoriasis. , 2021, , 419-430.		0
22	Overexpression of stromal periostin correlates with poor prognosis of cutaneous squamous cell carcinomas. <i>Experimental Dermatology</i> , 2021, 30, 698-704.	2.9	10
23	A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB). <i>JAAD International</i> , 2021, 2, 134-152.	2.2	7
24	Heralding change within dermatology: Response of the <i>International Journal of Women's Dermatology (IJWD)</i> to the twin pandemic of racism. <i>International Journal of Women's Dermatology</i> , 2021, 7, 125-126.	2.0	2
25	Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e412-e414.	2.4	28
26	Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI-16) analysis of randomized phase 2B study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1562-1568.	2.4	33
27	Are biosimilars for pemphigus safe?. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 942-943.	1.3	2
28	Managing epidermolysis bullosa during the coronavirus pandemic: Experience and ideals. <i>Clinics in Dermatology</i> , 2021, 39, 369-373.	1.6	2
29	Beyond the skin: disease parameters in pemphigus. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 147-150.	0.2	2
30	Intraepithelial autoimmune bullous dermatoses disease activity assessment and therapy. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1523-1537.	1.2	11
31	Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study*. <i>British Journal of Dermatology</i> , 2021, 185, 745-755.	1.5	42
32	Intraepithelial autoimmune blistering dermatoses: Clinical features and diagnosis. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1507-1519.	1.2	22
33	What instruments should we add to our toolbox for measuring the severity and control of eczema?. <i>British Journal of Dermatology</i> , 2021, 185, 13-14.	1.5	0
34	Impact of COVID-19 on inpatient dermatology consults in an Australian tertiary hospital. <i>Australasian Journal of Dermatology</i> , 2021, 62, 427-428.	0.7	4
35	Subepithelial autoimmune bullous dermatoses disease activity assessment and therapy. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 18-27.	1.2	12
36	European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1750-1764.	2.4	72

#	ARTICLE	IF	CITATIONS
37	European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1926-1948.	2.4	86
38	Individual patients' risk factors impact guidelines for prophylactic agents used in pemphigus patients treated with rituximab. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, e47-e48.	1.2	0
39	Subepithelial autoimmune blistering dermatoses: Clinical features and diagnosis. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1-14.	1.2	24
40	Hindi translation and validation of quality of life score in Indian patients with epidermolysis bullosa; and its correlation with the clinical severity assessment scores: A cross-sectional study. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2021, 88, 177-183.	0.6	2
41	State-of-the-art review of human autoimmune blistering diseases (AIBD). <i>Veterinary Dermatology</i> , 2021, 32, 524-e145.	1.2	0
42	GDF6 Knockdown in a Family with Multiple Synostosis Syndrome and Speech Impairment. <i>Genes</i> , 2021, 12, 1354.	2.4	5
43	Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus. <i>Frontiers in Medicine</i> , 2021, 8, 708071.	2.6	9
44	Assessing the quality of life in the families of patients with epidermolysis bullosa: The mothers as main caregivers. <i>International Journal of Women's Dermatology</i> , 2021, 7, 721-726.	2.0	7
45	Shedding light on the impact of hidradenitis suppurativa on women and their families: A focus of the International Journal of Women's Dermatology. <i>International Journal of Women's Dermatology</i> , 2021, 7, 661-663.	2.0	3
46	Evaluating diversity in Clinics in Dermatology. <i>Clinics in Dermatology</i> , 2021, 39, 1064-1066.	1.6	0
47	Patient-reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross-sectional survey. <i>Pediatric Dermatology</i> , 2021, 38, 1198-1201.	0.9	6
48	The impact of gender in mentor-mentee success: Results from the Women's Dermatologic Society Mentorship Survey. <i>International Journal of Women's Dermatology</i> , 2021, 7, 398-402.	2.0	11
49	Embracing diversity in dermatology: Creation of a culture of inclusion in dermatologic publishing. <i>International Journal of Women's Dermatology</i> , 2021, 7, 371-377.	2.0	1
50	Conducting dermatology clinical trials during the COVID-19 pandemic. <i>Clinics in Dermatology</i> , 2021, 39, 104-106.	1.6	6
51	Comparison of effectiveness of topical tacrolimus 0.1% vs topical halobetasol propionate 0.05% as an add-on to oral hydroxychloroquine in discoid lupus erythematosus. <i>Dermatologic Therapy</i> , 2021, 34, e14675.	1.7	2
52	Training and retaining physician scientists in dermatology: Australia. <i>JID Innovations</i> , 2021, 2, 100074.	2.4	1
53	Assessment of published literature regarding skin of color in <i>Pediatric Dermatology</i> . <i>Pediatric Dermatology</i> , 2021, 38, 1604-1605.	0.9	1
54	Diagnosis and management of pemphigus: Recommendations of an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 575-585.e1.	1.2	224

#	ARTICLE	IF	CITATIONS
55	Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 173-182.	2.9	183
56	Validation of the BIOCHIP test for the diagnosis of bullous pemphigoid, pemphigus vulgaris and pemphigus foliaceus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 153-160.	2.4	29
57	Novel diagnostic method to differentiate antilaminin-332 pemphigoid from other forms of pemphigoid. <i>British Journal of Dermatology</i> , 2020, 182, 270-271.	1.5	1
58	<i>Mycobacterium chelonae</i> infection mimicking <i>Demodex</i> folliculitis. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 469-470.	1.3	0
59	A prickly souvenir from a hedgehog café: tinea manuum secondary to <i>Trichophyton erinacei</i> via international spread. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 459-461.	1.3	1
60	The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 1.	2.7	129
61	Predatory journals: The silent intruder. <i>Dermatologic Therapy</i> , 2020, 33, e13214.	1.7	0
62	Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRN-473) in the treatment of canine pemphigus foliaceus. <i>Veterinary Dermatology</i> , 2020, 31, 291.	1.2	15
63	Drug-related adverse effects of vismodegib and sonidegib for locally advanced or metastatic basal cell carcinoma. <i>Australasian Journal of Dermatology</i> , 2020, 61, 176-177.	0.7	6
64	International collaboration. <i>Journal of Dermatological Treatment</i> , 2020, 31, 757-757.	2.2	1
65	Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. <i>British Journal of Dermatology</i> , 2020, 183, 614-627.	1.5	406
66	Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemic—Consensus: Recommendations by an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1222-1224.	1.2	7
67	Dermatology and specialty rotations: COVID-19 may reemphasize the importance of internal medicine. <i>Dermatologic Therapy</i> , 2020, 33, e13996.	1.7	2
68	Splicing of the cake can affect the severity of epidermolysis bullosa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1879-1880.	2.4	2
69	COVID-19 and immunosuppressive therapy in dermatology. <i>Dermatologic Therapy</i> , 2020, 33, e14140.	1.7	9
70	Wound closure in epidermolysis bullosa: data from the vehicle arm of the phase 3 ESSENCE Study. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 190.	2.7	9
71	Role of music therapy in reducing the burden of dermatological diseases during COVID-19. <i>Dermatologic Therapy</i> , 2020, 33, e14086.	1.7	3
72	Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology (EADV). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1900-1913.	2.4	159

#	ARTICLE	IF	CITATIONS
73	Financial burden of epidermolysis bullosa on patients in the United States. <i>Pediatric Dermatology</i> , 2020, 37, 1198-1201.	0.9	14
74	Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus. <i>Veterinary Dermatology</i> , 2020, 31, 410.	1.2	14
75	Outcomes and Predictors for Re-stenosis of Esophageal Stricture in Epidermolysis Bullosa. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020, 71, 310-314.	1.8	6
76	A dermatologist's perspective of the COVID-19 outbreak. <i>Dermatologic Therapy</i> , 2020, 33, e13538.	1.7	12
77	The response of the Women's Dermatologic Society and the International Journal of Women's Dermatology to the COVID-19 pandemic. <i>International Journal of Women's Dermatology</i> , 2020, 6, 129-130.	2.0	0
78	Use of face masks in dermatology department during the COVID-19 outbreak. <i>Dermatologic Therapy</i> , 2020, 33, e13521.	1.7	6
79	Sensitivity to change and correlation between the autoimmune bullous disease quality of life questionnaires ABQOL and TABQOL, and objective severity scores. <i>British Journal of Dermatology</i> , 2020, 183, 944-945.	1.5	6
80	Update on COVID-19 effects in dermatology specialty. <i>Dermatologic Therapy</i> , 2020, 33, e13523.	1.7	13
81	Restructuring an academic dermatology practice during the COVID-19 pandemic. <i>Dermatologic Therapy</i> , 2020, 33, e13684.	1.7	6
82	Virtual conferences of dermatology during the COVID-19 pandemic. <i>Dermatologic Therapy</i> , 2020, 33, e13774.	1.7	5
83	Should biologics for psoriasis be interrupted in the era of COVID-19?. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1217-1218.	1.2	141
84	Osteoporosis and bone health in autoimmune blistering skin disease—an evidenced based review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2745-2756.	2.4	1
85	Multiple milia formation in blistering diseases. <i>International Journal of Women's Dermatology</i> , 2020, 6, 199-202.	2.0	5
86	Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study). <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 158.	2.7	7
87	Treatment concerns for bullous pemphigoid in the COVID-19 pandemic era. <i>Dermatologic Therapy</i> , 2020, 33, e13956.	1.7	7
88	Successful dapson therapy in inherited epidermolysis bullosa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e333-e334.	2.4	5
89	The Potential Protective Effect of Estrogen: Why is COVID-19 mortality lower in females than males. <i>International Journal of Women's Dermatology</i> , 2020, 6, 152-153.	2.0	7
90	Autoimmune Bullous Disease Quality of Life (ABQoL) questionnaire: Validation of the translated Persian version in pemphigus vulgaris. <i>International Journal of Women's Dermatology</i> , 2020, 6, 306-310.	2.0	12

#	ARTICLE	IF	CITATIONS
91	Reply to: "COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution". Journal of the American Academy of Dermatology, 2020, 82, e215.	1.2	3
92	Treatment considerations for patients with pemphigus during the COVID-19 pandemic. Journal of the American Academy of Dermatology, 2020, 82, e235-e236.	1.2	53
93	Reply to: "Biologics for psoriasis during COVID-19 outbreak". Journal of the American Academy of Dermatology, 2020, 82, e219.	1.2	2
94	Where do we stand as dermatologists in combat with COVID-19. Dermatologic Therapy, 2020, 33, e13638.	1.7	8
95	Prevalence and pathogenesis of osteopenia and osteoporosis in epidermolysis bullosa: An evidence-based review. Experimental Dermatology, 2019, 28, 1122-1130.	2.9	12
96	Intra-rater reliability of the BIOCHIP indirect immunofluorescence dermatology mosaic in bullous pemphigoid and pemphigus patients. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2327-2333.	2.4	9
97	A chlorhexidine conundrum after an epidural delivery: The difficulty of differentiating between chlorhexidine burns and hypersensitivity reactions. International Journal of Women's Dermatology, 2019, 5, 269-270.	2.0	3
98	Patients left behind: Rare dermatologic conditions miss the orphan drug development boom. Journal of the American Academy of Dermatology, 2019, 81, 1025-1026.	1.2	0
99	What is novel in the clinical management of pemphigus. Expert Review of Clinical Pharmacology, 2019, 12, 973-980.	3.1	14
100	Pathogenesis and clinical features of alopecia in epidermolysis bullosa: A systematic review. Pediatric Dermatology, 2019, 36, 430-436.	0.9	4
101	Review of autoimmune blistering diseases: the Pemphigoid diseases. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1685-1694.	2.4	56
102	Autoimmune bullous diseases during pregnancy: Solving common and uncommon issues. International Journal of Women's Dermatology, 2019, 5, 166-170.	2.0	9
103	Successful management of bullous pemphigoid with dimethyl fumarate therapy: A case report. International Journal of Women's Dermatology, 2019, 5, 179-180.	2.0	5
104	Atopic Dermatitis Outcome Measures. , 2019, , 1-28.		0
105	Editorial: Skin Blistering Diseases. Frontiers in Medicine, 2019, 6, 60.	2.6	1
106	Pemphigus vulgaris accompanied with amyotrophic lateral sclerosis: a rare coincidence or pathogenic relationship?. European Journal of Dermatology, 2019, 29, 435-436.	0.6	0
107	Epidermolysis Bullosa Patients' Perception of Surgical Wound and Scar Healing. Dermatologic Surgery, 2019, 45, 280-289.	0.8	2
108	Diagnostic Criteria and Phenotypes of Pemphigoid and the Association With Gliptins. JAMA Dermatology, 2019, 155, 147.	4.1	1

#	ARTICLE	IF	CITATIONS
109	Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. <i>Journal of Investigative Dermatology</i> , 2019, 139, 31-37.	0.7	55
110	Assessment of the quality of life of Egyptian and Tunisian autoimmune bullous diseases™ patients using an Arabic version of the autoimmune bullous disease quality of life and the treatment of autoimmune bullous disease quality of life questionnaires. <i>Anais Brasileiros De Dermatologia</i> , 2019, 94, 399-404.	1.1	10
111	Atopic Dermatitis Outcome Measures. , 2019, , 1-28.		1
112	Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. <i>British Journal of Dermatology</i> , 2018, 178, 768-775.	1.5	127
113	International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita. <i>British Journal of Dermatology</i> , 2018, 179, 30-41.	1.5	62
114	Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 26-51.	6.5	158
115	Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference. <i>Frontiers in Medicine</i> , 2018, 5, 306.	2.6	27
116	Is the Oral Disease Severity Score going to be useful for dermatologists when assessing pemphigus?. <i>British Journal of Dermatology</i> , 2018, 179, 816-817.	1.5	3
117	A review of scoring systems for ocular involvement in chronic cutaneous bullous diseases. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 83.	2.7	13
118	The effect of autoimmune blistering diseases on work productivity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1959-1966.	2.4	10
119	APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	91
120	Topical Corticosteroids in Blistering Diseases. , 2018, , 91-100.		3
121	Chinese version of the treatment of autoimmune bullous disease quality of life questionnaire: Reliability and validity. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2018, 84, 431.	0.6	5
122	Why have hospitalization rates for bullous pemphigoid soared?. <i>British Journal of Dermatology</i> , 2017, 176, 5-6.	1.5	1
123	Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 543-546.	0.9	154
124	Measuring of quality of life in autoimmune blistering disorders in Poland. Validation of disease specific Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires. <i>Advances in Medical Sciences</i> , 2017, 62, 92-96.	2.1	23
125	Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. <i>BMC Cancer</i> , 2017, 17, 332.	2.6	291
126	Increasing prevalence but not incidence of psoriasis in the U.K.. <i>British Journal of Dermatology</i> , 2017, 176, 568-569.	1.5	0

#	ARTICLE	IF	CITATIONS
127	A comparison study of clinician-rated atopic dermatitis outcome measures for intermediate- to dark-skinned patients. <i>British Journal of Dermatology</i> , 2017, 176, 985-992.	1.5	37
128	An Atypical Localized Form of Hidradenitis Suppurativa of the Jawline and Neck Mimicking Severe Cystic Acne on Presentation. <i>Skin Appendage Disorders</i> , 2017, 3, 215-218.	1.0	6
129	Rituximab and short-course prednisone as the new gold standard for new-onset pemphigus vulgaris and pemphigus foliaceus. <i>British Journal of Dermatology</i> , 2017, 177, 1143-1144.	1.5	14
130	Highly Resistant Acrodermatitis Continua of Hallopeau and Pustular Psoriasis. <i>Skin Appendage Disorders</i> , 2017, 3, 179-181.	1.0	4
131	Reliability and validity of the Chinese version of the autoimmune bullous disease quality of life (ABQOL) questionnaire. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 31.	2.4	10
132	Digenic inheritance in epidermolysis bullosa simplex involving two novel mutations in <i>KRT5</i> and <i>KRT14</i> . <i>British Journal of Dermatology</i> , 2017, 177, 262-264.	1.5	9
133	The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 692-698.	2.4	28
134	The Reliability, Validity and Responsiveness of Two Disease Scores (BPDAI and ABSIS) for Bullous Pemphigoid: Which One to Use?. <i>Acta Dermato-Venereologica</i> , 2017, 97, 24-31.	1.3	36
135	Quality of Life in Greek Patients with Autoimmune Bullous Diseases Assessed with ABQOL and TABQOL Indexes. <i>Acta Dermato-Venereologica</i> , 2017, 97, 1145-1147.	1.3	10
136	Disease-specific health related quality of life patient reported outcome measures in Genodermatoses: a systematic review and critical evaluation. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 189.	2.7	8
137	Multiple sclerosis is the neurological disorder most highly associated with bullous pemphigoid. <i>British Journal of Dermatology</i> , 2017, 176, 1428-1429.	1.5	4
138	What is the true mortality from pemphigus?. <i>British Journal of Dermatology</i> , 2016, 174, 1185-1186.	1.5	4
139	Marked intrafamilial phenotypic heterogeneity in dystrophic epidermolysis bullosa caused by inheritance of a mild dominant glycine substitution and a novel deep intronic recessive <i>COL7A1</i> mutation. <i>British Journal of Dermatology</i> , 2016, 174, 1122-1125.	1.5	11
140	Calculation of cutoff values based on the Autoimmune Bullous Skin Disorder Intensity Score (TJETQ000rgBT/Overlock 10 Tf 50 2) for defining moderate, significant and extensive types of pemphigus. <i>British Journal of Dermatology</i> , 2016, 175, 142-149.	1.5	68
141	Chlorophyll-induced pseudoporphyria with ongoing photosensitivity after cessation – a case series of four patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1239-1242.	2.4	6
142	Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). <i>British Journal of Dermatology</i> , 2016, 175, 69-79.	1.5	115
143	Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in Australia. <i>Australasian Journal of Dermatology</i> , 2016, 57, 167-174.	0.7	53
144	Cover image: Unpeeling the layers of harlequin ichthyosis. <i>British Journal of Dermatology</i> , 2016, 174, 1160-1161.	1.5	1

#	ARTICLE	IF	CITATIONS
145	Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines. <i>British Journal of Dermatology</i> , 2016, 174, 56-67.	1.5	102
146	Clinical application of a molecular assay for the detection of dermatophytosis and a novel non-invasive sampling technique. <i>Pathology</i> , 2016, 48, 720-726.	0.6	12
147	Cover Image: The many faces of sarcoidosis. <i>British Journal of Dermatology</i> , 2016, 175, 1111-1112.	1.5	0
148	Translation, cross-cultural adaptation and validation of the Quality of Life Evaluation in Epidermolysis Bullosa instrument in Brazilian Portuguese. <i>International Journal of Dermatology</i> , 2016, 55, e94-9.	1.0	21
149	Suppression of TGF β 2 and Angiogenesis by Type VII Collagen in Cutaneous SCC. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv293.	6.3	63
150	A review of case-control studies on the risk factors for the development of autoimmune blistering diseases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 595-603.	2.4	11
151	Prevalence of anemia in patients with epidermolysis bullosa registered in Australia. <i>International Journal of Women's Dermatology</i> , 2015, 1, 37-40.	2.0	22
152	The reliability and validity of outcome measures for atopic dermatitis in patients with pigmented skin: A grey area. <i>International Journal of Women's Dermatology</i> , 2015, 1, 150-154.	2.0	30
153	Pigmented Hair-Thickening Fibers: A Camouflage Technique for Alopecia in Patients with Epidermolysis Bullosa. <i>Skin Appendage Disorders</i> , 2015, 1, 153-155.	1.0	6
154	Burden of disease scoring in epidermolysis bullosa. <i>British Journal of Dermatology</i> , 2015, 173, 1357-1358.	1.5	1
155	Advances in understanding and managing bullous pemphigoid. <i>F1000Research</i> , 2015, 4, 1313.	1.6	12
156	Autoimmune Blistering Diseases and Corticosteroid Use: A Review of the Evidence. , 2015, , 459-468.		2
157	Definitions and outcome measures for mucous membrane pemphigoid: Recommendations of an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 168-174.	1.2	133
158	Outcome measures for autoimmune blistering diseases. <i>Journal of Dermatology</i> , 2015, 42, 31-36.	1.2	27
159	Innate sensing of microbial products promotes wound-induced skin cancer. <i>Nature Communications</i> , 2015, 6, 5932.	12.8	113
160	Multiple cutaneous reticulohistiocytomas successfully treated with topical psoralen plus ultraviolet A therapy combined with intralesional injections of triamcinolone acetonide. <i>JAAD Case Reports</i> , 2015, 1, 157-159.	0.8	4
161	Age and etiology of childhood epidermolysis bullosa mortality. <i>Journal of Dermatological Treatment</i> , 2015, 26, 178-182.	2.2	31
162	Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 992-1002.	1.2	162

#	ARTICLE	IF	CITATIONS
163	Reliability of the autoimmune bullous disease quality of life (ABQOL) questionnaire in the USA. <i>Quality of Life Research</i> , 2015, 24, 2257-2260.	3.1	27
164	A pilot comparison study of four clinician-rated atopic dermatitis severity scales. <i>British Journal of Dermatology</i> , 2015, 173, 488-497.	1.5	32
165	Retrospective evidence on outcomes and experiences of pregnancy and childbirth in epidermolysis bullosa in Australia and New Zealand. <i>International Journal of Women's Dermatology</i> , 2015, 1, 26-30.	2.0	4
166	Recessive dystrophic epidermolysis bullosa (RDEB) complicated by secondary hepatic amyloidosis. <i>JAAD Case Reports</i> , 2015, 1, 337-339.	0.8	4
167	Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa. <i>European Journal of Dermatology</i> , 2015, 25, 30-32.	0.6	23
168	Genetic screening for human leukocyte antigen alleles prior to carbamazepine treatment. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1992-1993.	1.5	2
169	Cytoskeletal protein flightless I inhibits apoptosis, enhances tumor cell invasion and promotes cutaneous squamous cell carcinoma progression. <i>Oncotarget</i> , 2015, 6, 36426-36440.	1.8	25
170	Screening for infections prior to initiating immunosuppressive treatment for patients with autoimmune blistering diseases. <i>British Journal of Dermatology</i> , 2014, 171, 1285-1286.	1.5	0
171	Health-related Quality of Life in Epidermolysis Bullosa: Validation of the Dutch QOLEB Questionnaire and Assessment in the Dutch Population. <i>Acta Dermato-Venereologica</i> , 2014, 94, 442-447.	1.3	25
172	Inherited epidermolysis bullosa. <i>Journal of the Egyptian Women's Dermatologic Society</i> , 2014, 11, 1-13.	0.1	1
173	Scoring Systems for Blistering Diseases in Practice. <i>JAMA Dermatology</i> , 2014, 150, 245.	4.1	11
174	Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 89-97.e13.	1.2	57
175	Inherited epidermolysis bullosa: Updated recommendations on diagnosis and classification. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 1103-1126.	1.2	747
176	Management of pemphigus. <i>F1000prime Reports</i> , 2014, 6, 32.	5.9	11
177	Bullous pemphigoid: therapeutic algorithm and practical management. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 405-412.	0.8	1
178	A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 898-908.e7.	1.2	95
179	Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma. <i>British Journal of Dermatology</i> , 2013, 169, 208-210.	1.5	21
180	The development and validation of the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease. <i>British Journal of Dermatology</i> , 2013, 169, 1000-1006.	1.5	54

#	ARTICLE	IF	CITATIONS
181	Management of epidermolysis bullosa. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 279-293.	0.8	5
182	Development of a Quality-of-Life Instrument for Autoimmune Bullous Disease. <i>JAMA Dermatology</i> , 2013, 149, 1186.	4.1	70
183	A quantitative approach to histopathological dissection of elastin-related disorders using multiphoton microscopy. <i>British Journal of Dermatology</i> , 2013, 169, 869-879.	1.5	29
184	Towards global consensus on outcome measures for atopic eczema research: results of the <sc>HOME II</sc> meeting. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 1111-1117.	5.7	169
185	Diagnosis and Clinical Features of Pemphigus Vulgaris. <i>Immunology and Allergy Clinics of North America</i> , 2012, 32, 233-243.	1.9	32
186	Autoimmune Diseases of the Skin. <i>Immunology and Allergy Clinics of North America</i> , 2012, 32, xiii-xiv.	1.9	2
187	Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 479-485.	1.2	294
188	Inherited epidermolysis bullosa: New diagnostic criteria and classification. <i>Clinics in Dermatology</i> , 2012, 30, 70-77.	1.6	130
189	Fibroblast-Derived Dermal Matrix Drives Development of Aggressive Cutaneous Squamous Cell Carcinoma in Patients with Recessive Dystrophic Epidermolysis Bullosa. <i>Cancer Research</i> , 2012, 72, 3522-3534.	0.9	104
190	Preface. <i>Dermatologic Clinics</i> , 2011, 29, xv-xvi.	1.7	0
191	Evidence-Based Management of Bullous Pemphigoid. <i>Dermatologic Clinics</i> , 2011, 29, 613-620.	1.7	33
192	Hair Loss in Autoimmune Cutaneous Bullous Disorders. <i>Dermatologic Clinics</i> , 2011, 29, 503-509.	1.7	15
193	The International Pemphigus and Pemphigoid Foundation. <i>Dermatologic Clinics</i> , 2011, 29, 655-657.	1.7	3
194	Infection and Infection Prevention in Patients Treated with Immunosuppressive Medications for Autoimmune Bullous Disorders. <i>Dermatologic Clinics</i> , 2011, 29, 591-598.	1.7	21
195	Diagnosis and Clinical Features of Pemphigus Vulgaris. <i>Dermatologic Clinics</i> , 2011, 29, 373-380.	1.7	54
196	A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 903-908.	1.2	120
197	Advancement of women in dermatology. <i>International Journal of Dermatology</i> , 2011, 50, 593-600.	1.0	10
198	Outcomes of 11 pregnancies in three patients with recessive forms of epidermolysis bullosa. <i>British Journal of Dermatology</i> , 2011, 165, 700-701.	1.5	10

#	ARTICLE	IF	CITATIONS
199	A comparison in real clinical practice of methyl aminolevulinate photodynamic therapy and surgery for small superficial basal cell carcinoma: 3-year recurrence rates and cosmetic outcomes. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 117-118.	2.4	4
200	Diagnosis and Prevention of Bullous Diseases. , 2011, , 115-135.		0
201	Diagnosis and Prevention of Bullous Diseases. , 2011, , 53-73.		0
202	Epidemiology of Epidermolysis Bullosa in the Antipodes. <i>Archives of Dermatology</i> , 2010, 146, 635-40.	1.4	76
203	No Evidence That Human Papillomavirus Is Responsible for the Aggressive Nature of Recessive Dystrophic Epidermolysis Bullosaâ€‘Associated Squamous Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2853-2855.	0.7	12
204	Quality of Life Measurements in Epidermolysis Bullosa: Tools for Clinical Research and Patient Care. <i>Dermatologic Clinics</i> , 2010, 28, 185-190.	1.7	25
205	Epidermolysis Bullosa in Australia and New Zealand. <i>Dermatologic Clinics</i> , 2010, 28, 433-438.	1.7	14
206	Preface. <i>Dermatologic Clinics</i> , 2010, 28, xv-xvi.	1.7	1
207	Alopecia in Epidermolysis Bullosa. <i>Dermatologic Clinics</i> , 2010, 28, 165-169.	1.7	19
208	How to Take Skin Biopsies for Epidermolysis Bullosa. <i>Dermatologic Clinics</i> , 2010, 28, 197-200.	1.7	38
209	Preface. <i>Dermatologic Clinics</i> , 2010, 28, xix.	1.7	3
210	Treatment of pemphigus vulgaris and pemphigus foliaceus. <i>Expert Review of Dermatology</i> , 2009, 4, 469-481.	0.3	6
211	Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. <i>British Journal of Dermatology</i> , 2009, 161, 1323-1330.	1.5	106
212	Reliability and Convergent Validity of Two Outcome Instruments for Pemphigus. <i>Journal of Investigative Dermatology</i> , 2009, 129, 2404-2410.	0.7	183
213	Naevus of Ota presenting in two generations: a mother and daughter. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 102-104.	2.4	9
214	Mucous membrane pemphigoid: are laminin 5 antibodies a risk factor for laryngeal involvement?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 169-170.	2.4	11
215	Interventions for pemphigus vulgaris and pemphigus foliaceus. <i>The Cochrane Library</i> , 2009, , CD006263.	2.8	100
216	A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8â€‘20Âmm), with a 12â€‘month followâ€‘up.. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 1302-1311.	2.4	208

#	ARTICLE	IF	CITATIONS
217	Clinical heterogeneity in recessive epidermolysis bullosa due to mutations in the keratin 14 gene, <i>KRT14</i> . <i>Clinical and Experimental Dermatology</i> , 2008, 33, 689-697.	1.3	37
218	Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 1043-1046.	1.2	464
219	The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 931-950.	1.2	812
220	Treatment of Pemphigus. <i>Archives of Dermatology</i> , 2008, 144, 100-1.	1.4	17
221	A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. <i>British Journal of Dermatology</i> , 2007, 157, 954-959.	1.5	72
222	A Comparative Study Between Transmission Electron Microscopy and Immunofluorescence Mapping in the Diagnosis of Epidermolysis Bullosa. <i>American Journal of Dermatopathology</i> , 2006, 28, 387-394.	0.6	57
223	A complicated blistering disease case demonstrating the usefulness of immunoblotting and ELISA for the diagnosis of immunobullous diseases. <i>Australasian Journal of Dermatology</i> , 2006, 47, A57-A57.	0.7	2
224	Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. <i>British Journal of Dermatology</i> , 2005, 152, 1219-1227.	1.5	53
225	Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. <i>The Cochrane Library</i> , 2003, , CD004056.	2.8	44
226	Laminin 5 mutations in junctional epidermolysis bullosa: molecular basis of Herlitz vs non-Herlitz phenotypes. <i>Human Genetics</i> , 2002, 110, 41-51.	3.8	131
227	Epidermolysis Bullosa with Congenital Pyloric Atresia: Novel Mutations in the β ²⁴ Integrin Gene (ITGB4) and Genotype/Phenotype Correlations. <i>Pediatric Research</i> , 2001, 49, 618-626.	2.3	99
228	Autoantibodies to Type VII Collagen Recognize Epitopes in a Fibronectin-Like Region of the Noncollagenous (NC1) Domain. <i>Journal of Investigative Dermatology</i> , 1993, 100, 618-622.	0.7	87
229	Celebrating Outstanding Science at the European Academy of Dermatology and Venereology's 30th Anniversary Congress. <i>EMJ Dermatology</i> , 0, , 24-28.	0.0	0